AI summary · may contain errors
Tu-stroma, a serum extracellular vesicle long noncoding RNA, is elevated in STIC and early-stage HGSC and discriminates them from controls with AUCs up to 0.99.
- 1 cites
Moving in Nature Medicine.
Rebuilt
AI summary · may contain errors
Tu-stroma, a serum extracellular vesicle long noncoding RNA, is elevated in STIC and early-stage HGSC and discriminates them from controls with AUCs up to 0.99.
Newest first · last 60 days
AI summary · may contain errors
Neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) reduces unadjusted 30-day perioperative mortality versus primary debulking surgery (PDS) in women aged ≥70 with FIGO IIIC/IV epithelial ovarian cancer (RR=0.20).
AI summary · may contain errors
Stromal compartment profiles from matched clear cell, endometrioid, and high-grade serous ovarian cancers resolve into four shared groups (S1–S4), with S4 desmoplastic/myofibroblast-rich.
AI summary · may contain errors
Across 2,161 high-grade serous ovarian carcinoma tumors, tumor cellular composition predicts transcriptomic subtype in held-out cohorts with ROC-AUC 0.817–0.963.
AI summary · may contain errors
Tu-stroma, a serum extracellular vesicle long noncoding RNA, is elevated in STIC and early-stage HGSC and discriminates them from controls with AUCs up to 0.99.
AI summary · may contain errors
In HRgd children and adolescents with cancer at the Princess Máxima Center, 66.1% received standardised personalised oncofertility care, and 60.1% of those underwent fertility preservation methods.
AI summary · may contain errors
Non-Hispanic White individuals show the highest incidence of all gliomas, while Non-Hispanic Black individuals have the lowest incidence for multiple adult-type molecular subtypes, including IDH-mutant astrocytoma and oligodendroglioma.
AI summary · may contain errors
Low-dose alkylating chemotherapy (CED ≤8 g/m2) is linked to significant early follicle morphologic differences in human pre- and post-pubertal ovarian tissue, including altered oocyte and granulosa cell measures.
AI summary · may contain errors
AMH levels in female cancer survivors are higher at 12 and 24 months than at 6 months post-treatment, with breast cancer showing a 76.4% median AMH reduction at 12 months.
AI summary · may contain errors
Personalized neoantigen-targeting cancer vaccines showed safety and immune activity in high-grade epithelial ovarian cancer patients, with 75% of recurrent patients vaccinated.
AI summary · may contain errors
Updated ASCO living guideline evidence for epithelial ovarian cancer links PARPi use to progression-free survival benefits in frontline trials, while later-line and recurrent maintenance trials report potential overall survival disadvantages.
AI summary · may contain errors
Premenarcheal ovarian tissue from children (0–18 years) shows a higher prevalence of follicles with abnormal numbers of oocytes or nuclei, 65.0% vs 40.5% postmenarcheal (P = 0.013).
AI summary · may contain errors
Cre-mediated EGFRvIII overexpression with homozygous p19-ARF deletion in GFAP-expressing glial cells produces spontaneous classical glioblastoma lesions, with 95% of mice reaching endpoint symptoms by 6 months.
AI summary · may contain errors
In high-grade serous ovarian carcinoma, malignant secretory cells polarize along a SecA–SecB axis, with SecB enrichment in hypoxic niches linked to poor survival.
AI summary · may contain errors
BRCA-mutated high-grade serous ovarian cancer shows stronger interferon-α/γ and inflammatory immune enrichment within the IC7 immune-enriched spatial region than BRCA-WT tumors.
AI summary · may contain errors
Earlier follow-up is recommended for low-risk but measurable ovarian lesions classified by the Ovarian-Adnexal Reporting and Data System, to improve ongoing monitoring.
AI summary · may contain errors
Carboplatin plus mirvetuximab soravtansine achieved an investigator-assessed objective response rate of 62.7% in recurrent platinum-sensitive ovarian cancer with folate receptor alpha (FRα) ≥50% expression.
AI summary · may contain errors
HRDPath predicts homologous recombination deficiency in high-grade serous ovarian carcinoma with an AUC of 0.846, outperforming previous methods across three patient cohorts.
AI summary · may contain errors
Proteogenomic profiling of 112 pediatric and AYA high-grade glioma patients (ages 0–40) reveals two age-defined AYA subgroups with distinct molecular profiles and survival outcomes.
AI summary · may contain errors
In high-grade serous ovarian cancer, liver metastases show marked clonal and microenvironmental heterogeneity, but direct molecular evidence from hepatic lesions remains sparse.
AI summary · may contain errors
Comprehensive genomic profiling plus molecularly guided therapy improved progression-free survival versus continued platinum chemotherapy in unfavorable cancer of unknown primary, with median PFS 6.1 vs 4.4 months.
AI summary · may contain errors
Chemotherapy-refractory high-grade serous ovarian carcinoma shows lower type-I interferon and EMT balance scores in a single-cell cohort of nine libraries, with a small hypoxia increase.
AI summary · may contain errors
Carboplatin-resistant ovarian cancer patient-derived xenografts are enriched for chondroitin-4-sulfate (C4S), and this stromal C4S state is linked to platinum response differences.
AI summary · may contain errors
Neoadjuvant olaparib plus pembrolizumab in HRD-positive stage III–IV high-grade serous or endometrioid ovarian cancer achieved a 70% overall response rate (95% CI 45.7–88.1).
AI summary · may contain errors
DNA damage response and biomarker-defined vulnerabilities in recurrent or treatment-resistant gynecological malignancies show encouraging clinical activity, including targets like WEE1, PKMYT1, WRN, and CCNE1 amplification.
Journals this month
Topics moving, week to 17 Nov 2026
By field